By: Karolinska Institutet From: medicalxpress.com Low doses of the investigational medicinal product endoxifen reduce breast density to the same extent as the standard treatment tamoxifen, but without causing such troublesome side effects. This is shown by a new study from Karolinska Institutet published in the Journal of the National Cancer Institute. The results may have implications for future preventive treatment …
FDA Approves Vepdegestrant for ER+/HER2– Advanced Breast Cancer With an ESR1 Mutation
By: Chris Ryan From: onclive.com The FDA has approved vepdegestrant (Veppanu) for the treatment of adult patients with estrogen receptor (ER)–positive, HER2-negative, ESR1-mutated advanced or metastatic breast cancer, as detected by an FDA-authorized test, with disease progression following at least 1 line of endocrine therapy.1,2 The approval was backed by data from the phase 3 VERITAC-2 trial (NCT05654623), which demonstrated …
Datopotamab Deruxtecan Improves Survival Outcomes in Advanced Triple-Negative Breast Cancer
By: Quincy Attobrah From: oncnursingnews.com Datopotamab deruxtecan (Datroway) demonstrated improved progression-free survival (PFS) and overall survival (OS) compared with standard chemotherapy in patients with previously untreated, advanced triple-negative breast cancer (TNBC) who were not eligible for immunotherapy, according to results from the phase 3 TROPION-Breast02 trial. The findings, published in Annals of Oncology, address a significant unmet need in TNBC, …
Updates In HER2-Low Breast Cancer Treatment Strategies
HER2-low breast cancer has changed one of the most familiar classifications in breast oncology. For many years, tumors that were not HER2-positive were generally managed as HER2-negative disease, with treatment decisions driven by hormone receptor status, prior therapy, disease tempo, and chemotherapy sensitivity. The development of trastuzumab deruxtecan has changed this framework by making low HER2 expression clinically actionable in …
Study uncovers potential cancer treatment that is readily available
By: Bryana Quintana From: sdsu.edu A treatment for the most common type of breast cancer may already exist. As reported in a December paper in Nature Communications, San Diego State University researchers who were part of an international study believe they found one. Associate professor of biology Svasti Haricharan initially approached her early research wondering, “Why do some people get …
Oral Paclitaxel DHP107 Non-inferior to IV for Metastatic Breast Cancer
From: oncnursingnews.com Patients with HER2-negative metastatic breast cancer may soon have a more convenient treatment option, as the phase 3 OPTIMAL trial (NCT03315364) confirms that DHP107, a novel oral paclitaxel formulation, is non-inferior to traditional intravenous (IV) paclitaxel. From January 2018 to December 2023, researchers at 51 sites across South Korea, China, and Europe evaluated 549 patients to determine if …
Understanding Breast Cancer Tumor Size Staging
From: healthline.com Key takeaways Breast cancer staging uses tumor size and location, plus spread to lymph nodes and other organs, to show how advanced the cancer is. Doctors describe tumor size using the TNM System “T” categories, from T1 (less than 2 centimeters) to T4 (when it invades the chest wall or skin). Tumor size and staging help guide treatment …
Breast Cancer Hijacks the Lung Repair System to Fuel Tumor Growth, Study Finds
By: Laura Kelley From: cuanschutz.edu Researchers at the CU Anschutz Cancer Center have discovered how breast cancer cells that spread to the lungs may take advantage of the body’s natural healing response and how a commonly used drug might slow that process. They found that breast cancer cells that spread to the lungs trigger the lung’s normal repair system, creating …
Delaying Pegfilgrastim May Curb Bone Pain in Breast Cancer
By; Frederik Joelving From: medscape.com Women given pegfilgrastim to prevent myelosuppression after chemotherapy for breast cancer often develop bone pain — but a small clinical trial suggests that delaying the drug by just one extra day can lessen the side effect. Researchers found that beginning pegfilgrastim (Neulasta) on day 3 after the final chemotherapy dose reduced the incidence of severe …
Pyrotinib-Based Dual Anti-HER2 Regimen Extended Survival in Metastatic Breast Cancer
By: Mary Ellen Schneider From: cancertherapyadvisor.com Pyrotinib plus trastuzumab and docetaxel outperformed trastuzumab and docetaxel alone as an initial treatment for HER2-positive metastatic breast cancer, according to findings published in the BMJ. The final analysis of the phase 3 PHILA taril (NCT03863223) demonstrated significant improvements in both progression-free survival (PFS) and overall survival (OS). “Pyrotinib, a small molecule, irreversible, pan-HER …